EichorEICHOR
Condition: Hematologic Cancers Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Hematologic Cancers

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical
EARLY_Phase 1 · 1 location(s) · National Cancer Institute, Naples · NCT07577206Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07670130Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
NA · 1 location(s) · Second Affiliated Hospital, Zhejiang University, School of M · NCT06881511Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Th
Phase N/A · 1 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT07014865Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · 11 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT06375044The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acu
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06458257e-Motion : Promoting Emotion Regulation in Chronic Cancer
NA · 2 location(s) · Université Libre de Bruxelles · NCT07236021Study of the Medullary Microenvironment in Acute Childhood Leukemia
NA · 3 location(s) · University Hospital, Tours · NCT05792007A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · 124 location(s) · Janssen Research & Development, LLC · NCT07258511The Norwegian Immunotherapy in Multiple Myeloma Study
Phase N/A · 23 location(s) · St. Olavs Hospital · NCT06855121BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT06644443A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT05074355Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06581640Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06046313Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 · 1 location(s) · Mayo Clinic · NCT06940297A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 · 10 location(s) · Kelonia Therapeutics, Inc. · NCT07075185CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT06059391Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06589089A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Phase 3 · 28 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT06464991A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Phase 1 · 8 location(s) · Janssen Research & Development, LLC · NCT07572006Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Mye
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07283224Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Phase 1 · 4 location(s) · CERo Therapeutics Holdings, Inc. · NCT06834282Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Phase 1/Phase 2 · 21 location(s) · Technische Universität Dresden · NCT04385290Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT07228273uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Phase 2 · 6 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05900882HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT055860743'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.